JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Predictive score for response to neoadjuvant chemotherapy in early-stage HR + /HER2- breast cancer

  • 0Medical Oncology Department, Centro Hospitalar Universitário de Santo António - Unidade Local de Saúde de Santo António, Porto, Portugal. v.joao.q.coelho@gmail.com.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico +

|

February 6, 2025

|

February 6, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Predicting neoadjuvant chemotherapy (NACT) response in HR+/HER2- breast cancer is crucial. Tumor grade, menopausal status, and intrinsic subtype significantly impact pathological response, enabling personalized treatment decisions.

Area Of Science

  • Oncology
  • Breast Cancer Research
  • Chemotherapy Efficacy

Background

  • Neoadjuvant chemotherapy (NACT) is a treatment for early-stage hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer.
  • Pathological response rates to NACT in this subtype are often suboptimal, with limited understanding of individual risk factors.
  • Identifying predictive biomarkers is essential for optimizing NACT in HR+/HER2- breast cancer.

Purpose Of The Study

  • To identify significant biomarkers associated with pathological response to NACT in HR+/HER2- breast cancer.
  • To develop a predictive score for NACT response based on identified clinicopathological variables.
  • To facilitate personalized therapeutic decision-making for patients with HR+/HER2- breast cancer.

Main Methods

  • Retrospective, single-center study of 101 patients with stage IIA-IIIC HR+/HER2- breast cancer treated with NACT and surgery (2019-2023).
  • Multiple logistic regression analysis was employed to assess associations between clinicopathological variables and pathological response (partial/complete vs. absent).
  • The best-performing predictive model was utilized to construct a risk score for NACT response.

Main Results

  • Tumor grade (G2/3 vs. G1) was a significant predictor of pathological response.
  • Menopausal status (pre- vs. post-menopausal) emerged as another key factor influencing NACT response.
  • Intrinsic subtype (luminal B vs. A) also demonstrated a significant association with pathological response.

Conclusions

  • A dynamic calculator incorporating tumor grade, hormonal status, intrinsic subtype, and Ki-67 was developed.
  • This tool offers real-time input to aid in personalized therapeutic strategies for HR+/HER2- breast cancer.
  • The findings support tailored treatment decisions based on individual patient and tumor characteristics.

Keywords: